(Donanemab)Biosimilar Reference Antibody-GS40190主打 新品

货号：GS40190

Donanemab is a humanized monoclonal antibody approved for the treatment of early symptomatic Alzheimer's disease (AD), including mild cognitive impairment (MCI) and mild dementia stages with confirmed amyloid pathology. Marketed under the brand name Kisunla®, it specifically targets and promotes the clearance of a modified, deposited form of amyloid-beta (Aβ) in the brain. In pivotal clinical trials, donanemab significantly slowed cognitive and functional decline compared to placebo and led to high rates of amyloid plaque clearance, providing a disease-modifying therapy for eligible patients.